Kamban Hirasen to Antitubercular Agents
This is a "connection" page, showing publications Kamban Hirasen has written about Antitubercular Agents.
Connection Strength
0,802
-
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
Score: 0,502
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,191
-
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
Score: 0,110